Imugene Ltd
IMU
Company Profile
Business description
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
Contact
4-6 Bligh Street
Suite 12.01, Level 12
SydneyNSW2000
AUSSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
5
Stocks News & Analysis
stocks
James Hardie transfers of share listing to New York Stock Exchange
The change is a result of the controversial Azek acquisition.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,926.20 | 80.60 | -0.89% |
| CAC 40 | 7,798.22 | 24.45 | -0.31% |
| DAX 40 | 24,307.80 | 18.29 | 0.08% |
| Dow JONES (US) | 44,344.52 | 2.33 | 0.01% |
| FTSE 100 | 9,012.99 | 20.87 | 0.23% |
| HKSE | 24,994.14 | 168.48 | 0.68% |
| NASDAQ | 20,983.99 | 88.34 | 0.42% |
| Nikkei 225 | 39,819.11 | 82.08 | -0.21% |
| NZX 50 Index | 12,961.51 | 81.11 | 0.63% |
| S&P 500 | 6,308.30 | 11.51 | 0.18% |
| S&P/ASX 200 | 8,668.20 | 89.00 | -1.02% |
| SSE Composite Index | 3,559.79 | 25.31 | 0.72% |